The Rainmaker, interesting post regarding p-values and have you ever seen many pre-clinical posted p-values?
.001 is certainly quite impressive, but what would you think of a p-valoue of .0048 in a pre-clinical setting for combination immunotherapy treatment ?
Pre-clinical is seldom the place where any biotech dares to find the resulting p-value, or I should say dares to publish it.... because in pre-clinical its seldom successful. Phase III I see some biotechs increasing and increasing their n... in order to just reach a good p-value that the FDA will like. Combination therapy / immunotherapy will be the biggest portion of all biotechs pipelines in percentage of revenue in the near term and here we have a global biomarker in flipped PS, that seems to be one hell of a biotech value.
I'm here solely for the biotech value of a lifetime.... and I sense we are at the very beginning of the beginning here.
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.